This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
by Zacks Equity Research
Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
pharmaceuticals
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
by Kinjel Shah
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
pharmaceuticals
Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
by Kanishka Das
MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.
pharmaceuticals
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
biotechnology biotechs medical pharmaceuticals
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
biotechnology biotechs medical pharmaceuticals
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
by Zacks Equity Research
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
biotechnology biotechs medical pharmaceuticals
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
by Zacks Equity Research
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
biotechnology biotechs medical pharmaceuticals
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
pharmaceuticals
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
by Zacks Equity Research
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
biotechnology biotechs immuno-therapy medical pharmaceuticals
J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.
pharmaceuticals